Skin Laxity Clinical Trial
Official title:
Pilot Study: Clinical Assessment of Bipolar Radiofrequency Microneedling for Improved Laxity and Wrinkles of the Suprapatellar Skin
Verified date | November 2020 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The human skin aging process is characterized by thinning dermis, atrophy of the extracellular matrix, and reduced collagen synthesis. Loss of collagen in the dermis is of aesthetic concern, as it is the main structural support in the dermis and its loss results in skin laxity. Photo-damaged skin, mostly due to UVR, causes degradation of elastic fibers. This is histologically seen as disorganized tangles of elastin. Additionally, as humans age, skin tends to appear more dry due to its poor hydration and turgor capacity. The use of minimally invasive aesthetic treatments in reducing signs of aging has been gaining in popularity over surgical treatments in recent years. Several energy types including, laser, radiofrequency, infrared, and ultrasound, have been developed for facial rejuvenation. These treatments induce controlled thermal damage into the dermis and cause collagen contraction and neocollagenesis resulting in skin tightening over several months. For improving appearance of other anatomical areas, micro-focused ultrasound has been the preferred method, but has shown limited success in tightening the suprapatellar skin. As with facial skin aging, the suprapatellar skin loses elasticity with age and begins to sag. Noninvasive treatments used for the face may also be used in other anatomical areas to produce the same effects of tightening. Minimally invasive bipolar radiofrequency produces a controlled thermal injury in a fractional manner without damaging the dermal-epidermal junction, epidermis or subcutis. Radiofrequency, unlike lasers, are chromophore-independent providing better penetration than lasers, and spare sweat glands, sebaceous glands, and hair follicles.
Status | Completed |
Enrollment | 20 |
Est. completion date | May 1, 2019 |
Est. primary completion date | January 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Healthy male and female adults between ages 18-75 years of age. - Subjects who can read, understand, and sign the Informed Consent Form. - Subjects willing and able to comply with all study requirements - Fitzpatrick skin type I-III Exclusion Criteria: - Subjects with active localized or systemic infections. - Immunocompromised subjects. - Subjects with coagulation disorder. - History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs). - Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study). - In the opinion of the trained clinician, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits. - Subjects with a history of radiation therapy to the treatment area. - Subject has a history of allergy to lidocaine or ester-based local anesthetics. - Subjects with any skin pathology or condition that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments. - Subjects have undergone dermatological procedures (e.g., laser or light treatments) for the treatment of wrinkles, skin resurfacing, or skin rejuvenation in the treatment area within 1 year of study participation. |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
United States,
Alexiades-Armenakas M, Newman J, Willey A, Kilmer S, Goldberg D, Garden J, Berman D, Stridde B, Renton B, Berube D, Hantash BM. Prospective multicenter clinical trial of a minimally invasive temperature-controlled bipolar fractional radiofrequency system for rhytid and laxity treatment. Dermatol Surg. 2013 Feb;39(2):263-73. doi: 10.1111/dsu.12065. Epub 2012 Dec 28. — View Citation
Alster TS, Tanzi EL. Noninvasive lifting of arm, thigh, and knee skin with transcutaneous intense focused ultrasound. Dermatol Surg. 2012 May;38(5):754-9. doi: 10.1111/j.1524-4725.2012.02338.x. Epub 2012 Jan 23. — View Citation
Gold M, Taylor M, Rothaus K, Tanaka Y. Non-insulated smooth motion, micro-needles RF fractional treatment for wrinkle reduction and lifting of the lower face: International study. Lasers Surg Med. 2016 Oct;48(8):727-733. doi: 10.1002/lsm.22546. Epub 2016 Aug 4. — View Citation
Hantash BM, Ubeid AA, Chang H, Kafi R, Renton B. Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. Lasers Surg Med. 2009 Jan;41(1):1-9. doi: 10.1002/lsm.20731. — View Citation
Tobin DJ. Introduction to skin aging. J Tissue Viability. 2017 Feb;26(1):37-46. doi: 10.1016/j.jtv.2016.03.002. Epub 2016 Mar 14. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Photographic Knee Laxity and Texture Evaluation | Photographs will be used to evaluate efficacy of treatment. The photographs from final visit will be compared to their baseline photographs and visually evaluated by the study team. The study team will assess the laxity from baseline to 6 months. | baseline and 6 months | |
Primary | Epidermal Thickness | Skin Elasticity will be measured via BTC2000 prior to treatment (baseline), 7 days, 3 weeks, 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. | baseline, 7 Days, 3 Weeks, 3 Months and 6 Months | |
Primary | Dermal Thickness | Dermal thickness will be masured via high resolution ultrasound prior to treatment (baseline), 7 days, 3 weeks, 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. | Baseline, 7 Days, 3 Weeks, 3 Months and 6 Months | |
Primary | Change in Blood Flow at 0.25mm | Blood Flow will be measured via optical coherence tomography prior to treatment (baseline), 7 days, 3 weeks, 3 months and 6 months post treatment. | Baseline, Day 7, Week 3 Month 3 and Month 6 | |
Primary | Transepidermal Water Loss | Transepidermal Water Loss will be masured via Aquaflux prior to treatment (baseline), 7 days, 3 weeks, 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. | Baseline, Day 7, Week 3, Month 3 and Month 6 | |
Primary | Skin Elasticity | Skin Elasticity will be measured via BTC2000 prior to treatment (baseline), 7 days, 3 weeks, 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. | Baseline, Day 7, Week 3, Months 3 and Months 6 | |
Primary | Change in Skin Laxity | BTC2000 will be used to measure skin laxity prior to treatment and post treatment. The BTC2000 is a non-invasive device that measures skin laxity by creating a negative pressure against the skin and calculates laxity when the pressure is released. | baseline, 7 days, 3 weeks, 3 months and 6 months | |
Primary | Histological Analysis- Collagen 1 | Relative changes in protein abundance in biopsies taken at post treatment compare to control or entreated group will be quantified using an image processing software based on fluorescence signal intensity. The change from baseline was calculated at each time frame. | Baseline. Day 7 and 3 Months | |
Primary | Gene Expression- Collagen 1 | Biopsies of the treated are will be taken prior to treatment and post treatment for gene expression analysis. This analysis will identify gene expression related to collagen formation and increased cell turnover. Fold change was calculated at each time point past baseline.
Fold change = sample/average of the baseline. |
Day 7, Month 3 | |
Primary | Epidermal Density | Epidermal thickness will be masured via high resolution ultrasound prior to treatment (baseline), 7 days, 3 weeks, 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. | Baseline, Day 7, Week 3, Month 3 and Month 6 | |
Primary | Histological Analysis- Collagen 3 | Relative changes in protein abundance in biopsies taken at post treatment compare to control or entreated group will be quantified using an image processing software based on fluorescence signal intensity. The change from baseline was calculated at each time frame. Sample/Average of the baseline. | Baseline, Day 7, Month 3 | |
Primary | Histological Analysis- Elastin | Relative changes in protein abundance in biopsies taken at post treatment compare to control or entreated group will be quantified using an image processing software based on fluorescence signal intensity. The change from baseline was calculated at each time frame. Samples/Average of the baseline | Baseline, Day 7, Month 3 | |
Primary | Gene Expression- Collagen 3 | Biopsies of the treated are will be taken prior to treatment and post treatment for gene expression analysis. This analysis will identify gene expression related to collagen formation and increased cell turnover.
Fold change = sample/average of the baseline. |
Day 7, Month 3 | |
Primary | Gene Expression- Elastin | Biopsies of the treated are will be taken prior to treatment and post treatment for gene expression analysis. This analysis will identify gene expression related to collagen formation and increased cell turnover.
Fold change = sample/average of the baseline. |
Day 7, Month 3 | |
Primary | Gene Expression- Interluekin 6 | Biopsies of the treated are will be taken prior to treatment and post treatment for gene expression analysis. This analysis will identify gene expression related to collagen formation and increased cell turnover.
Fold change = sample/average of the baseline. |
Day 7, Month 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06140628 -
A 28-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Completed |
NCT01713985 -
Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck
|
N/A | |
Completed |
NCT01971736 -
Efficacy of Long Pulsed 1064nm Laser for Facial Skin Tightening
|
N/A | |
Completed |
NCT01708382 -
Feasibility Study: Lifting and Tightening of the Elbows
|
N/A | |
Completed |
NCT01713998 -
Treatment of the Face and Neck With Lower Ulthera System Energy Settings
|
N/A | |
Completed |
NCT01708252 -
Feasibility Study: Treatment of Post-surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ulthera Treatment
|
N/A | |
Completed |
NCT04296201 -
Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology
|
N/A | |
Completed |
NCT06000839 -
A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)
|
N/A | |
Completed |
NCT06366503 -
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation
|
N/A | |
Completed |
NCT05929625 -
Radiofrequency and Ultrasound for Improvement of Skin Laxity and Wrinkles: Efficacy and Safety Evaluation
|
N/A | |
Terminated |
NCT01713569 -
Feasibility Study: Histological Characterization After Treatment With the Ulthera® System
|
N/A | |
Completed |
NCT01519934 -
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
|
N/A | |
Completed |
NCT05605691 -
Post-Market Lower Eyelid Treatment With Renuvion in Greece
|
N/A | |
Completed |
NCT04477187 -
Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
|
N/A | |
Completed |
NCT05590364 -
Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
|
N/A | |
Active, not recruiting |
NCT06243744 -
Histological Evaluation of Human Skin Bx to Assess the Effects of APR Tx as an Adjunct Procedure in Facelift Surgery
|
N/A | |
Completed |
NCT04146584 -
Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow
|
Phase 2 | |
Recruiting |
NCT05750901 -
Evaluation of Fractional Ablative Laser Treatment for Skin Conditions
|
N/A | |
Completed |
NCT04721600 -
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
|
N/A | |
Recruiting |
NCT06157567 -
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
|
N/A |